东莞证券8月21日发布研报称，给予亿纬锂能（300014.SZ）买入评级。评级理由主要包括：1）若剔除 股权激励费用及单项坏账计提，公司2025年上半年实现业绩同比增长；2）动力电池出货同比大幅增 长，46系列大圆柱率先量产；3）储能电池业务增长持续强劲，客户结构调整有望带来盈利能力回升。 风险提示：下游需求不及预期风险；市场竞争加剧风险；新产品新技术迭代风险；原材料价格大幅波动 风险。 （文章来源：每日经济新闻） ...

Core Viewpoint - Aidi Kang Holdings (09860) reported a mid-term performance for the six months ending June 30, 2025, with revenue of RMB 1.271 billion, a year-on-year decrease of 13.31% [1] Financial Performance - The company's total revenue reached RMB 1.271 billion, reflecting a decline of 13.3% year-on-year [1] - Profit attributable to equity holders of the parent company was RMB 27.273 million, down 73.15% year-on-year [1] - Earnings per share stood at RMB 0.04 [1] Business Segments - The co-construction business revenue grew by 30% year-on-year, with a four-year compound annual growth rate (CAGR) of 48%, primarily driven by successful projects with major tertiary hospitals [1] - The CRO (Contract Research Organization) business revenue increased by 18% year-on-year, supported by deep collaborations with leading domestic and international pharmaceutical companies [1] - The company maintained a strong position in the diabetes sector, achieved robust performance in the NASH (Non-Alcoholic Steatohepatitis) field, and made innovative breakthroughs in solid tumor treatment, expanding its business landscape [1] Future Outlook - The company plans to deepen strategic cooperation with leading medical institutions in the second half of the year to promote more benchmark projects [1]

Group 1 - The company's operating revenue for the first half of 2025 reached 1.28 billion yuan, representing a year-on-year growth of 15.91% [1] - The net profit for the same period was 11.06 million yuan, showing a significant year-on-year increase of 234.32% [1]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company has shown an accelerating revenue trend, with domestic operations contributing to performance elasticity. In Q2 2025, the company achieved revenue of 201 million yuan, a year-on-year increase of 30.95%, indicating a positive outlook due to improved domestic and international economic conditions [2] - The company is a global leader in providing recombinant proteins to industrial clients and is expected to benefit from ongoing expansion in domestic and international markets, leading to sustained upward growth in performance [3] Financial Performance Summary - For the first half of 2025, the company reported operating revenue of 387 million yuan, a year-on-year increase of 29.38%, and a net profit attributable to shareholders of 84 million yuan, up 47.81% year-on-year [1] - The company’s R&D expenses for the first half of 2025 were 90 million yuan, a year-on-year increase of 15.19%, reflecting a commitment to high-intensity R&D investment [7] - The revenue from the recombinant protein business in the first half of 2025 was 319 million yuan, a year-on-year increase of 26%, while the antibody and reagent business generated 50 million yuan, up 48% year-on-year [7] Future Outlook - The company has adjusted its revenue forecasts for 2025-2027, with expected revenues of 841 million yuan, 1.055 billion yuan, and 1.307 billion yuan respectively, and adjusted EPS for the same period to 1.09 yuan, 1.41 yuan, and 1.78 yuan [3] - The company’s net profit margin is projected to improve, with net profit growth rates of 47.1%, 29.7%, and 26.3% for 2025, 2026, and 2027 respectively [9]

同时，名创优品宣布派发中期股息，每股ADS股息为0.29美元，上半年股份回购及派发股息合计约10.7 亿元，占经调整净利润的84%，上半年股份回购金额已超过2024全年，持续为股东带来丰厚回报。 格隆汇8月22日｜昨晚公布业绩的名创优品(9896.HK)今日大涨，盘中一度涨超20%，报47.16港元，股价 创今年1月以来新高；截至目前成交额放大至18.7亿港元。 公司公布财报显示，2025年二季度总营收达49.7亿元，同比增长23.1%；毛利率44.3%，较去年同期上升 40个基点；经调整净利润(Non-IFRS)6.9亿元，同比增长10.6%；经调整净利率13.9%，经调整每股ADS 收益同比上升12.0%，展现出强劲的业务韧性和稳健的盈利能力。 ...

Group 1 - The company reported a mid-year revenue of approximately RMB 856.2 million for 2025, representing a year-on-year growth of 17.6% [2] - The net profit for the period was approximately RMB 50.3 million, showing a year-on-year increase of 19.2% [2] - Revenue growth was observed across various segments, with the most significant increase in maintenance and repair services [2] Group 2 - The company's gross profit reached RMB 263.8 million, reflecting a year-on-year growth of 20.1% [2] - The gross margin improved to 30.8%, driven by enhancements in maintenance and repair service margins, contributions from new electric loader business, and the integration of the high-end brand Liziou (Shanghai) [2]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company achieved a revenue growth of 25% year-on-year in Q2 2025, indicating significant results from its reform efforts [8] - The company is recognized as a well-known domestic daily chemical brand with a comprehensive brand matrix and extensive channel coverage [8] - The report highlights a turning point in operations as the company actively adjusts its brand, products, and marketing strategies [8] Financial Performance Summary - For H1 2025, the company reported a total revenue of 3.48 billion yuan, a year-on-year increase of 4.7%, and a net profit attributable to shareholders of 270 million yuan, up 11.7% year-on-year [8] - In Q2 2025, the company achieved a revenue of 1.77 billion yuan, a year-on-year increase of 25.4%, and a net profit of 50 million yuan, marking a turnaround [8] - The gross margin for H1 2025 was 63.37%, an increase of 2.24 percentage points year-on-year, while the gross margin for Q2 2025 was 63.34%, up 5.09 percentage points year-on-year [8] - The report forecasts net profits for 2025-2027 to be 320 million, 410 million, and 540 million yuan respectively, with year-on-year growth rates of 139%, 27%, and 32% [8] Segment Performance Summary - The personal care and beauty segments showed high growth, with Q2 2025 revenues of 800 million yuan and 420 million yuan, representing year-on-year increases of 42.4% and 55.7% respectively [8] - The online sales channel in Q2 2025 saw a revenue increase of 34.6%, with online and offline sales accounting for 44.2% and 55.8% respectively [8] Brand and Product Development - The company has launched upgraded products and collaborated with popular IPs, leading to increased market share in key categories [8] - The brand "Six God" ranked first in various online sales categories, contributing to a 3 percentage point increase in market share for its mosquito repellent products [8]

Group 1 - The core viewpoint of the article highlights the significant increase in rare earth prices, particularly praseodymium and neodymium, which is expected to benefit companies in the sector, including Jinli Permanent Magnet [1] - As of August 21, the price of praseodymium oxide reached 657,500 yuan/ton, an increase of 110,000 yuan/ton from the beginning of the month, representing a rise of over 20% [1] - The price of neodymium oxide also rose to 657,500 yuan/ton, with an increase of 115,000 yuan/ton from the start of the month, reflecting a year-to-date increase of 62.95% [1] Group 2 - Jinli Permanent Magnet reported a revenue of approximately 3.507 billion yuan for the first half of the year, marking a year-on-year growth of 4.33% [1] - The company's net profit attributable to shareholders reached 305 million yuan, showing a substantial year-on-year increase of 154.81% [1] - The non-recurring net profit attributable to shareholders was 234 million yuan, which represents a remarkable year-on-year growth of 588.18% [1] Group 3 - Citic Construction Investment indicated that the expectation of downstream inventory replenishment makes rare earth prices likely to rise, while historical trends suggest that high overseas prices often lead to domestic price increases [1] - The article suggests that the improvement in rare earth metal prices is enhancing the profitability of companies in the sector, leading to a dual boost in valuation and profits [1] - Jinli Permanent Magnet's clear development path and continuous growth in rare earth permanent magnet production capacity are expected to drive both volume and price increases in its performance [1]

Group 1 - The core viewpoint of the report is that Guokang Co., Ltd. (605077.SH) is rated as "better than market" due to its expected performance and strategic moves [2] - The company's net profit attributable to shareholders is projected to decline by 3.38% year-on-year in the first half of 2025, primarily due to increased depreciation from the Zhoushan Huakang Project's first phase capacity conversion [2] - The orderly commissioning of new capacity in Zhoushan is expected to significantly boost the company's performance [2] - The company plans to acquire Yuxin Sugar Alcohol through cash and equity, which will strengthen its leading position in the xylitol industry [2]

公司最新毛利率为35.76%，较上季度毛利率增加0.39个百分点，较去年同期毛利率增加0.29个百分点，实现4年连续上涨。最新ROE为15.45%，较去年同期 ROE增加2.84个百分点。 2025年8月22日，纽威股份(603699.SH)发布2025年中报。 公司营业总收入为34.04亿元，较去年同报告期营业总收入增加5.66亿元，实现3年连续上涨，同比较去年同期上涨19.96%。归母净利润为6.37亿元，较去年 同报告期归母净利润增加1.49亿元，实现3年连续上涨，同比较去年同期上涨30.44%。经营活动现金净流入为9.13亿元，较去年同报告期经营活动现金净流 入增加8.42亿元，同比较去年同期上涨1188.94%。 公司股东户数为1.25万户，前十大股东持股数量为5.74亿股，占总股本比例为74.63%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 王保庆 | 15.8. | | 2 | 程章文 | 15.8. | | ന 席超 | | 10.8 | | ব 陆斌 | | 10.8. | | 5 | 香港中央结算有限公司 | 8.1 ...